Xspray Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	151.1	203.88	169.57	109.6	58.38	Upgrade
Research & Development	10.75	79.36	40.26	22.22	38.57	Upgrade
Other Operating Expenses	-6.43	-	-29.06	-0.44	-	Upgrade
Operating Expenses	155.42	283.24	180.77	131.38	96.95	Upgrade
Operating Income	-155.42	-283.24	-180.77	-131.38	-96.95	Upgrade
Interest Expense	-16.85	-1.93	-0.68	-0.01	-0	Upgrade
Interest & Investment Income	2.22	3.3	2.73	1.42	1.26	Upgrade
Currency Exchange Gain (Loss)	-1.49	-3.79	-0.96	-1.69	-1	Upgrade
Other Non Operating Income (Expenses)	-0	-0	-	-	-0	Upgrade
EBT Excluding Unusual Items	-171.55	-285.66	-179.68	-131.67	-96.7	Upgrade
Gain (Loss) on Sale of Assets	-	-0.02	-0.01	-	-	Upgrade
Pretax Income	-171.55	-285.67	-179.68	-131.67	-96.7	Upgrade
Income Tax Expense	-0.1	-0.15	-0.02	-	-	Upgrade
Net Income	-171.44	-285.52	-179.67	-131.67	-96.7	Upgrade
Net Income to Common	-171.44	-285.52	-179.67	-131.67	-96.7	Upgrade
Shares Outstanding (Basic)	38	33	27	21	19	Upgrade
Shares Outstanding (Diluted)	38	33	27	21	19	Upgrade
Shares Change (YoY)	16.04%	24.61%	26.21%	9.53%	11.77%	Upgrade
EPS (Basic)	-4.46	-8.62	-6.76	-6.25	-5.03	Upgrade
EPS (Diluted)	-4.46	-8.62	-6.76	-6.25	-5.03	Upgrade
Free Cash Flow	-193.16	-226.75	-205.97	-134.65	-52.92	Upgrade
Free Cash Flow Per Share	-5.02	-6.84	-7.75	-6.39	-2.75	Upgrade
EBITDA	-149.84	-277.76	-174.27	-123.04	-89.07	Upgrade
D&A For EBITDA	5.58	5.48	6.49	8.34	7.89	Upgrade
EBIT	-155.42	-283.24	-180.77	-131.38	-96.95	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.